TY - JOUR
T1 - On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs
T2 - Study protocol for a hybrid design randomized controlled trial
AU - Frimpong, Jemima A.
AU - D'Aunno, Thomas
AU - Perlman, David C.
AU - Strauss, Shiela M.
AU - Mallow, Alissa
AU - Hernandez, Diana
AU - Schackman, Bruce R.
AU - Feaster, Daniel J.
AU - Metsch, Lisa R.
N1 - Funding Information:
The research reported in this publication is supported by NIDA under award number R34DA038530. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to thank members of the study sites who are supporting this study. Alissa Mallow was with Promesa Inc. of the Acacia Network at the time of submission.
Publisher Copyright:
© 2016 Frimpong et al.
PY - 2016/3/3
Y1 - 2016/3/3
N2 - Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25% of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD). Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs. Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades. Trial registration: ClinicalTrials.gov: NCT02355080.
AB - Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25% of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD). Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs. Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades. Trial registration: ClinicalTrials.gov: NCT02355080.
KW - Adoption of evidence-based practices
KW - Bundled HIV/HCV testing
KW - HCV testing
KW - HIV testing
KW - Hybrid intervention-implementation research
KW - Implementation research
KW - Intervention adaptation
KW - Substance use disorder treatment
UR - http://www.scopus.com/inward/record.url?scp=84959263846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959263846&partnerID=8YFLogxK
U2 - 10.1186/s13063-016-1225-4
DO - 10.1186/s13063-016-1225-4
M3 - Article
C2 - 26936623
AN - SCOPUS:84959263846
SN - 1745-6215
VL - 17
JO - Trials
JF - Trials
IS - 1
M1 - 117
ER -